NCCN eBulletin - NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

The updated NCCN Guidelines for Non-Small Cell Lung Cancer now include a description of maintenance therapy for patients with advanced or metastatic disease. This new section helps distinguish between recommended therapies for continuation maintenance versus switch maintenance.

Erlotinib has been added as a first-line treatment option for EGFR mutation positive patients with advanced or metastatic disease with a category 2A designation. Bevacizumab and cetuximab have been added as treatment options for continuation maintenance with a category 1 designation. Pemetrexed and erlotinib have been added as treatment options for switch maintenance with a category 2B designation and docetaxel has been added as a treatment option for switch maintenance with a category 3 designation.

For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology™, the NCCN Drugs & Biologics Compendium™, and the NCCN Chemotherapy Order Templates™ please visit NCCN.org.

National Comprehensive Cancer Network

About NCCN

NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

The NCCN Clinical Practice Guidelines in Oncology™ for Non-Small Cell Lung Cancer Have Been Updated and Published as Version 1.2010